New
GHK-Cu
35,00 €
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- A significant increase in collagen synthesis and improved skin firmness.
- Accelerated healing and reduced scarring.
- Stimulation of the hair follicle and improvement in hair density.
- Systemic anti-aging effect through modulation of gene expression.
- Systemic antioxidant and anti-inflammatory action.
- Bone Regeneration and Nerve Repair in Research Models.
Description
GHK-Cu (copper peptide)
Skin / Anti-Aging / Systemic
MECHANISM OF ACTION
A natural copper-binding tripeptide (Gly-His-Lys). It chelates Cu2+ ions, allowing them to enter cells. It modulates the expression of more than 4,000 human genes, including the upregulation of collagen I and III, elastin, decorin, and wound-healing genes. It activates tissue remodeling, anti-inflammatory, and antioxidant pathways. It stimulates GHK-responsive genes in skin fibroblasts, nerve cells, and systemic tissues.
KEY BENEFITS
- A significant increase in collagen synthesis and improved skin firmness.
- Accelerated healing and reduced scarring.
- Stimulation of the hair follicle and improvement in hair density.
- Systemic anti-aging effect through modulation of gene expression.
- Systemic antioxidant and anti-inflammatory action.
- Bone Regeneration and Nerve Repair in Research Models.
SIDE EFFECTS AND SAFETY
Excellent safety profile. Topical use: mild skin irritation at high concentrations. Injectable: reactions at the injection site. Excess copper intake should be monitored in patients with Wilson’s disease or hemochromatosis.
RESEARCH AND CLINICAL NOTES
Pickart et al.: More than 40 years of research. It has been shown to modulate 31.2% of more than 4,000 genes related to wound healing and anti-aging. Clinical studies demonstrate a reduction in wrinkles and an improvement in skin density and elasticity. Hair growth trials show follicular stimulation.
TARGET PROFILE:
Aesthetic medicine, dermatology, hair restoration, and longevity medicine.
Additional information
| Weight | ,26 kg |
|---|
You may also like…
Hot
Algal Oil Omega 3 EPA/DHA, 100 capsules
- Vegan source of Omega-3: Schizochytrium microalgae oil, a sustainable alternative to fish oil.
- Cardiovascular health: DHA and EPA help reduce triglycerides, improve circulation, and control blood pressure.
- Brain and cognitive wellness: Supports memory, concentration, and prevents cognitive decline.
- Eye health: DHA is an essential component of the retina, helping maintain optimal vision.
- Anti-inflammatory properties: Alleviates symptoms of arthritis and other chronic inflammatory diseases.
- Suitable for vegans: Free from gluten, lactose, and preservatives.
Related products
New
AOD-9604
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Targeted fat loss without IGF-1-mediated growth effects.
- No effect on blood glucose or insulin sensitivity.
- Fat reduction is well tolerated in patients with metabolic disorders and diabetes.
- It supports body recomposition when combined with exercise.
- Being investigated for cartilage repair (TGA approval in Australia for OA).
New
CJC-1295 5 mg without DAC + IPA 5 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Synergistic optimization of endogenous GH secretion.
- Reference GH Peptide Stack for Body Composition.
- Increased lean body mass, fat loss, and recovery.
- Maintenance of the pulsatile rhythm of GH, with lower long-term risk.
- Ipamorelin's selectivity minimizes the increase in cortisol and prolactin.
New
NAD+
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Optimization of cellular energy and efficiency in ATP production.
- Activation of sirtuins for the epigenetic regulation of longevity.
- Repair of DNA damage through PARP activation.
- Improved mitochondrial biogenesis.
- Cognitive clarity and support for neurological function.
- Applications in research on addiction and depression.
New
Retatrutide 10 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
New
Retatrutide 20 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
New
Semaglutide
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Average body weight reduction of 15–17% with 2.4 mg per week.
- A 1.5–2.0% reduction in HbA1c.
- A 20% reduction in MACE in the SELECT trial among an obese, non-diabetic population.
- Remission of NASH in clinical trials.
- Reduced cravings for substances and alcohol, according to emerging data.
- Potential cognitive protection in dementia research.
Snap-8
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Non-invasive wrinkle reduction equivalent to botulinum toxin, though gentler and safer.
- Reduction in the depth of dynamic wrinkles on the forehead, crow's feet, and glabellar lines.
- Used in conjunction with Matrixyl and GHK-Cu in comprehensive anti-aging regimens.
- Active ingredient for cosmetic formulations or injectable administration.
- The preferred alternative for patients seeking options that do not involve botulinum toxin.
New
Thymosin Alpha-1
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Restoration of T-cell immunity in immunocompromised patients.
- Reduction of viral load in hepatitis B and C.
- Adjunctive use in HIV, cancer immunotherapy, and sepsis.
- Improving the immune response to vaccines in older adults.
- Anti-inflammatory action through immune balance and Th1/Th2 regulation.
- Adjunctive use in COVID-19, with significant evidence from China and Italy.
